Genetic Testing for Prostate Cancer

(PROMISE Trial)

This trial focuses on building a large database of prostate cancer patients with specific genetic changes known as germline pathogenic variants. The researchers aim to understand how these genetic changes affect patient outcomes and treatment success. Participants will provide a saliva sample for genetic testing and share their health and family history. Patients with a confirmed prostate cancer diagnosis—through biopsy, high PSA levels, or disease evidence on scans—and residing in the U.S. or its territories, are welcome to join. This trial connects participants with new research and treatment opportunities based on their genetic information. As an unphased study, it offers participants a unique chance to contribute to groundbreaking research that could lead to personalized treatment options.

The trial information does not specify whether you need to stop taking your current medications. It seems focused on genetic testing and data collection rather than altering treatment plans.

Research has shown that the PROMISE Registry provides a safe method for learning more about prostate cancer and genetic risks. Participants provide a saliva sample for genetic testing, a simple and low-risk process. The main goal is to gather information and track health over time. The registry does not involve any treatments or drugs. Instead, it connects patients with potential clinical trials based on their genetic information. As the registry focuses on data collection rather than administering new treatments, participation carries no direct risk.¹²³⁴⁵

Researchers are excited about the PROMISE Registry because it aims to uncover how specific genetic mutations in prostate cancer patients affect treatment success and survival rates. Unlike typical treatments that focus solely on targeting cancer cells, this registry is exploring the genetic makeup of individuals to personalize treatment strategies. By understanding the unique germline mutations present in each patient, there's potential to tailor treatments more effectively, leading to improved outcomes compared to the one-size-fits-all approach of traditional therapies. This method could pave the way for more precise and successful treatments in the future.

Research has shown that genetic differences can greatly affect how prostate cancer patients respond to treatment. The PROMISE Registry, a nationwide study, aims to understand how these genetic differences influence treatment success and survival rates. Participants in this trial will be grouped based on their genetic profiles: one group will include those with at least one variant of uncertain significance, and another group will include those with at least one germline pathogenic or likely pathogenic variant. Early results suggest that certain inherited genetic changes can affect treatment response. By studying these changes, researchers aim to customize treatments for greater effectiveness. This registry will gather long-term data to identify the best treatment options for patients with specific genetic profiles.¹²³⁴⁶